These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 30580095)

  • 1. Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis.
    Farhang Zangneh H; Wong WWL; Sander B; Bell CM; Mumtaz K; Kowgier M; van der Meer AJ; Cleary SP; Janssen HLA; Chan KKW; Feld JJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1840-1849.e16. PubMed ID: 30580095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
    J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
    Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
    Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication.
    Espina Cadena S; Casas Deza D; Julián Gomara B; Borao Laguna CV; Sierra Gabarda O; Lamuela Calvo LJ; Lorente S; Serrano T; Arbonés Mainar JM; Bernal Monterde V
    Rev Esp Enferm Dig; 2024 Jun; 116(6):305-311. PubMed ID: 38214165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of hepatocellular carcinoma and fibrosis evolution in hepatitis C patients with severe fibrosis or cirrhosis treated with direct acting antiviral agents.
    Hamoir C; Horsmans Y; Stärkel P; Dahlqvist G; Negrin Dastis S; Lanthier N
    Acta Gastroenterol Belg; 2021; 84(1):25-32. PubMed ID: 33639690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan.
    Younossi ZM; Tanaka A; Eguchi Y; Henry L; Beckerman R; Mizokami M
    J Viral Hepat; 2018 Aug; 25(8):945-951. PubMed ID: 29478258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
    Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
    Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
    Sanduzzi-Zamparelli M; Mariño Z; Lens S; Sapena V; Iserte G; Pla A; Granel N; Bartres C; Llarch N; Vilana R; Nuñez I; Darnell A; Belmonte E; García-Criado A; Díaz A; Muñoz-Martinez S; Ayuso C; Bianchi L; Fuster-Anglada C; Rimola J; Forner A; Torres F; Bruix J; Forns X; Reig M
    J Hepatol; 2022 Apr; 76(4):874-882. PubMed ID: 34856322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: Who to screen and for how long?
    Ahumada A; Rayón L; Usón C; Bañares R; Alonso Lopez S
    World J Gastroenterol; 2021 Oct; 27(40):6737-6749. PubMed ID: 34790004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C.
    Ioannou GN; Green PK; Beste LA; Mun EJ; Kerr KF; Berry K
    J Hepatol; 2018 Nov; 69(5):1088-1098. PubMed ID: 30138686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinician's guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective.
    McEwan P; Selvapatt N; Brown A; Thursz M; Bennett H; Webster S; Kalsekar A; Yuan Y; Brenner M; Gordon J
    Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):208-214. PubMed ID: 27832039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis.
    Kim HL; An J; Park JA; Park SH; Lim YS; Lee EK
    Hepatology; 2019 Apr; 69(4):1599-1613. PubMed ID: 30365164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
    Singal AG; Lim JK; Kanwal F
    Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC.
    Roche B; Coilly A; Duclos-Vallee JC; Samuel D
    Liver Int; 2018 Feb; 38 Suppl 1():139-145. PubMed ID: 29427487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
    Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
    J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.